COST-EFFECTIVENESS OF DAPAGLIFLOZIN PLUS STANDARD TREATMENT COMPARED TO STANDARD TREATMENT FOR THE MANAGEMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION IN COLOMBIA

被引：0
|
作者：
Rojas, Gil Y. [1 ]
Lasalvia, P. [1 ]
Pena, Garcia A. A. [2 ]
机构：
[1] NeuroEconomix, Bogota, Colombia
[2] Hosp San Ignacio, Bogota, Colombia
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 01期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
POSB161
引用
收藏
页码：S92 / S92
页数：1
相关论文
共 50 条
  • [1] Cost-utility of dapagliflozin plus standard treatment compared to standard treatment for the management of heart failure with reduced ejection fraction in Colombia
    Gil-Rojas, Yaneth
    Lasalvia, Pieralessandro
    Garcia, Angel
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (04) : 655 - 663
  • [2] Cost-effectiveness of adding dapagliflozin to standard treatment for heart failure with reduced ejection fraction patients in China
    Yao, Younan
    Zhang, Rongcheng
    An, Tao
    Zhao, Xinke
    Zhang, Jian
    ESC HEART FAILURE, 2020, 7 (06): : 3582 - 3592
  • [3] Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction
    Isaza, Nicolas
    Calvachi, Paola
    Raber, Inbar
    Liu, Chia-Liang
    Bellows, Brandon K.
    Hernandez, Inmaculada
    Shen, Changyu
    Gavin, Michael C.
    Garan, A. Reshad
    Kazi, Dhruv S.
    JAMA NETWORK OPEN, 2021, 4 (07) : E2114501
  • [4] Cost-effectiveness of dapagliflozin plus standard treatment compared to standard therapy for the management of chronic kidney disease in Colombia
    Lasalvia, Pieralessandro
    Vasquez, M. Eliana C.
    Alvarez, Jose Javier Arango
    Garcia-Padilla, Paola
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2024, 24 (10) : 1133 - 1143
  • [5] Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction
    Parizo, Justin T.
    Goldhaber-Fiebert, Jeremy D.
    Salomon, Joshua A.
    Khush, Kiran K.
    Spertus, John A.
    Heidenreich, Paul A.
    Sandhu, Alexander T.
    JAMA CARDIOLOGY, 2021, 6 (08) : 926 - 935
  • [6] Cost-effectiveness of dapagliflozin and empagliflozin for treatment of heart failure with reduced ejection fraction
    Nguyen, Bao-Ngoc
    Mital, Shweta
    Bugden, Shawn
    V. Nguyen, Hai
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2023, 376 : 83 - 89
  • [7] Dapagliflozin for the treatment of heart failure with reduced ejection fraction in Brazil: a cost-effectiveness analysis
    Naves, Marcio Coutinho Xavier
    Amato, Angelica Amorim
    Zimmermann, Ivan Ricardo
    Peixoto, Henry Maia
    LANCET REGIONAL HEALTH-AMERICAS, 2025, 42
  • [8] Cost-effectiveness of Dapagliflozin in Heart Failure With Reduced Ejection Fraction
    Isaza, Nicolas
    Calvachi, Paola
    Raber, Inbar
    Shen, Changyu
    Gavin, Michael C.
    Garan, A. Reshad
    Bellows, Brandon K.
    Kazi, Dhruv S.
    CIRCULATION, 2020, 142
  • [9] COST-EFFECTIVENESS OF DAPAGLIFLOZIN VERSUS SACUBITRIL/VALSARTAN FOR THE TREATMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION
    McEwan, P.
    Darlington, O.
    Bergenheim, K.
    Qin, L.
    VALUE IN HEALTH, 2020, 23 : S494 - S494
  • [10] COST-EFFECTIVENESS OF DAPAGLIFLOZIN IN THE TREATMENT OF CHRONIC SYMPTOMATIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN THE NETHERLANDS
    Kvamme, I
    de Graaf, G.
    Nekerman, S.
    Gijsbers, S.
    Wester, V
    Hoogendoorn, M.
    VALUE IN HEALTH, 2022, 25 (12) : S170 - S170
12345